Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07441109
NA

Shatavari Root Extract for Perimenopausal Symptoms

Sponsor: SF Research Institute, Inc.

View on ClinicalTrials.gov

Summary

This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract in women experiencing perimenopausal symptoms. Participants will receive either Shatavari root extract or a matched placebo for 12 weeks. Efficacy will be assessed using validated menopause-specific symptom, quality-of-life, stress, mood, and sleep questionnaires, along with physiological stress markers. Safety will be evaluated through laboratory assessments and adverse event monitoring.

Official title: Efficacy and Safety of Shatavari (Asparagus Racemosus) Root Extract for Treatment of Perimenopausal Symptoms in Women: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study

Key Details

Gender

FEMALE

Age Range

40 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-03-11

Completion Date

2026-06-29

Last Updated

2026-03-03

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

Shatavari (Asparagus racemosus) Root Extract

A standardized Shatavari root extract manufactured under cGMP conditions with an herb-to-extract ratio of 13:1 and standardized to contain ≥10% total Shatavarins. Participants will self-administer one capsule daily for 12 weeks.

OTHER

Placebo Capsule

An inert starch-filled capsule identical in appearance, color, and packaging to the active intervention, administered once daily for 12 weeks to maintain blinding.

Locations (1)

San Francisco Research Institute

San Francisco, California, United States